Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Neos Therapeutics Inc Rose 13.7% In October


Why Neos Therapeutics Inc Rose 13.7% In October

Shares of Neos Therapeutics (NASDAQ: NEOS), a small-cap pharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), jumped 13.7% in October according to data from S&P Global Market Intelligence. It was a month filled with news, but October's rally can be pinpointed to a single event.

Here's a quick review of the company-specific news items that took place in October:

While those updates were interesting, the company's stock didn't take off until shareholders learned that PDL BioPharma (NASDAQ: PDLI) had made an unsolicited bid to acquire the company outright. PDL -- which is a biopharma with a checkered history -- offered to buy all of the company's outstanding shares for $10.25 in cash. Since shares were trading around $7.30 prior to the announcement, they jumped hugely after the news broke.

Continue reading


Source: Fool.com

Neos Therapeutics Inc Stock

€0.93
-8.590%
Heavy losses for Neos Therapeutics Inc today as the stock fell by -€0.095 (-8.590%).

Like: 0
Share

Comments